These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10657826)

  • 21. Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-effectiveness of a universal screening programme for St. Maarten.
    van Heyningen AM; Levenston MJ; Tamminga N; Scoop-Martijn EG; Wever RM; Verhagen AA; van der Dijs FP; Dijck-Brouwer DA; Offriinga PJ; Muskiet FA
    West Indian Med J; 2009 Sep; 58(4):301-4. PubMed ID: 20099768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of neonatal screening for sickle cell disease.
    Lane PA; Eckman JR
    J Pediatr; 1992 Jan; 120(1):162-3. PubMed ID: 1731017
    [No Abstract]   [Full Text] [Related]  

  • 24. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening.
    Kunz JB; Awad S; Happich M; Muckenthaler L; Lindner M; Gramer G; Okun JG; Hoffmann GF; Bruckner T; Muckenthaler MU; Kulozik AE
    Ann Hematol; 2016 Feb; 95(3):397-402. PubMed ID: 26658910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neonatal haemoglobinopathy screening in Spain.
    Mañú Pereira M; Corrons JL
    J Clin Pathol; 2009 Jan; 62(1):22-5. PubMed ID: 19103853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.
    Davies SC; Cronin E; Gill M; Greengross P; Hickman M; Normand C
    Health Technol Assess; 2000; 4(3):i-v, 1-99. PubMed ID: 10840658
    [No Abstract]   [Full Text] [Related]  

  • 27. A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola.
    McGann PT; Grosse SD; Santos B; de Oliveira V; Bernardino L; Kassebaum NJ; Ware RE; Airewele GE
    J Pediatr; 2015 Dec; 167(6):1314-9. PubMed ID: 26477868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of long-term impacts of universal newborn hearing screening.
    Chiou ST; Lung HL; Chen LS; Yen AM; Fann JC; Chiu SY; Chen HH
    Int J Audiol; 2017 Jan; 56(1):46-52. PubMed ID: 27598544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost and cost-effectiveness of universal screening for hearing loss in newborns.
    Kezirian EJ; White KR; Yueh B; Sullivan SD
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):359-67. PubMed ID: 11283492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Costing model for neonatal screening and diagnosis of haemoglobinopathies.
    Cronin EK; Normand C; Henthorn JS; Hickman M; Davies SC
    Arch Dis Child Fetal Neonatal Ed; 1998 Nov; 79(3):F161-7. PubMed ID: 10194984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is universal neonatal hemoglobinopathy screening cost-effective?
    Bergman AB
    Arch Pediatr Adolesc Med; 1995 Apr; 149(4):466-7. PubMed ID: 7704180
    [No Abstract]   [Full Text] [Related]  

  • 32. Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action.
    Colombatti R; Martella M; Cattaneo L; Viola G; Cappellari A; Bergamo C; Azzena S; Schiavon S; Baraldi E; Dalla Barba B; Trafojer U; Corti P; Uggeri M; Tagliabue PE; Zorloni C; Bracchi M; Biondi A; Basso G; Masera N; Sainati L
    Pediatr Blood Cancer; 2019 May; 66(5):e27657. PubMed ID: 30724025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Paper-Based Test for Screening Newborns for Sickle Cell Disease.
    Piety NZ; George A; Serrano S; Lanzi MR; Patel PR; Noli MP; Kahan S; Nirenberg D; Camanda JF; Airewele G; Shevkoplyas SS
    Sci Rep; 2017 Apr; 7():45488. PubMed ID: 28367971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
    Salcedo J; Bulovic J; Young CM
    Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Low-Income Setting.
    Alvarez OA; Hustace T; Voltaire M; Mantero A; Liberus U; Saint Fleur R
    Pediatrics; 2019 Oct; 144(4):. PubMed ID: 31530717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antenatal screening for haemoglobinopathies in primary care: a cohort study and cluster randomised trial to inform a simulation model. The Screening for Haemoglobinopathies in First Trimester (SHIFT) trial.
    Dormandy E; Bryan S; Gulliford MC; Roberts TE; Ades AE; Calnan M; Atkin K; Karnon J; Barton PM; Logan J; Kavalier F; Harris HJ; Johnston TA; Anionwu EN; Davis V; Brown K; Juarez-Garcia A; Tsianakas V; Marteau TM
    Health Technol Assess; 2010 Apr; 14(20):1-160. PubMed ID: 20416236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.
    Sisk JE; Whang W; Butler JC; Sneller VP; Whitney CG
    Ann Intern Med; 2003 Jun; 138(12):960-8. PubMed ID: 12809452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.
    Hoerger TJ; Harris R; Hicks KA; Donahue K; Sorensen S; Engelgau M
    Ann Intern Med; 2004 May; 140(9):689-99. PubMed ID: 15126252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.
    Paulukonis ST; Eckman JR; Snyder AB; Hagar W; Feuchtbaum LB; Zhou M; Grant AM; Hulihan MM
    Public Health Rep; 2016; 131(2):367-75. PubMed ID: 26957672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.